Figure 2 The US Centers for Disease Control and

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Life expectancy at birth in all countries included

Figure 1 Perivenous distribution of multiple sclerosis lesions

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Time course of the development of physiological changes

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Schematic illustration of different clinical trial designs

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 General framework of brain–computer interface (BCI) systems

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The burden of chronic kidney disease (CKD)

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 2 Grey matter atrophy in FTD

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Translational research projects in LGMD

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Allele frequency and effect size for ALS-associated genes

Figure 2 Algorithm for immunosuppressive treatment

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Principles of therapeutic ultrasound

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 3 Ascending pain pathways and the brain regions involved

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 6 Vascular dysfunction in epilepsy

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Clinical aspects of LGMD subtypes

Figure 1 Tau PET images in patients with Alzheimer disease

Figure 2 Cellular pathways implicated in CIPN

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Figure 7 Overview of the methodological processes for

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Figure 1 [18F]florbetapir standardized uptake value ratio analytical method [18F]florbetapir standardized uptake value ratio analytical method Flowchart.

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Overview of the imaging biomarker roadmap

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Network connections of the hypothalamus

Figure 2 Aβ-PET scans obtained using different tracers

Presentation transcript:

Figure 2 The US Centers for Disease Control and Prevention Office of Public Health Genomics ACCE Model Project Figure 2 | The US Centers for Disease Control and Prevention Office of Public Health Genomics ACCE Model Project. The ACCE (analytic validity, clinical validity, clinical utility and associated ethical, legal and social implications) model is a framework of four key factors set out by the Centers for Disease Control and Prevention Office of Public Health Genomics to evaluate new genetic tests for validity and utility. This model can also be applied to the field of neuroimaging-based biomarkers of pain, which is currently in a research discovery phase. Davis, K. D. et al. (2017) Brain imaging tests for chronic pain: medical, legal and ethical issues and recommendations Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.122